NCT01196247

CompletedPhase 2

A Study of Therapy Selected by Molecular/Metabolic Profiling...

Translational Drug Development Source

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

SU2C-001

Study Type

interventional

Actual enrollment (reported)

35

Locations

1 country

Sites

1

Timeline

Study Start

September 2010

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

November 2011

Actual (reported)

Study Completion

February 2012

Actual (reported)

Brief Summary

The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 35 participants
Study completion date: February 2012
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
September 2010
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 3, 2010
Actual (reported)
First Posted
September 8, 2010
Actual (reported)
Primary Completion
November 2011
Actual (reported)
Study Completion
February 2012
Actual (reported)

Last Updated: July 17, 2012
Status Verified: July 2012
Last Update Submitted: July 16, 2012

Conditions

Previously Treated Metastatic Pancreatic Cancer

Keywords

pancreatic cancermolecular profilingSU2CSecond line therapyStage 4

Outcome Measures

Primary Outcomes (1)

Determine the percent of patients who are alive at one year
Goal is to improve the one year survival (from start of first-line therapy for metastatic disease) to 60%
One year

Interventions

Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBankDrug

FDA approved drugs as indicated by molecular profiling

Also known as: FDA approved drugs as indicated by molecular profiling

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

metastatic adenocarcinoma of the pancreas
male or non-pregnant female

Sponsors & Collaborators

Translational Drug Development
Otherlead
Scottsdale Healthcare
Othercollaborator
Stand Up To Cancer

Study Sites (1)

TGen Clinical Research Services at Scottsdale Healthcare

Scottsdale, Arizona, 85258, United States

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

Comparative Genomic Hybridization

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Cytogenetic AnalysisGenetic TechniquesInvestigative Techniques

Study Officials

Ramesh Ramanathan, MD
TGen
PRINCIPAL INVESTIGATOR

Enrollment

35 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER

Study Record Dates

First Submitted

September 3, 2010

First Posted

September 8, 2010

Study Start

September 2010

Date type not reported

This date has not been verified as actual or estimated.

years of age or greater

one prior therapy for the treatment of metastatic disease

must start continuation therapy within 9 months of starting first line treatment

have adequate organ and bone marrow function

must have a Karnofsky performance status greater than or equal to 70

one or more metastatic tumors measurable by CT scan and accessible for biopsy

You may not qualify if:

operable or locally advanced pancreatic cancer
metastatic tumor that is not amendable to biopsy
known brain mets unless previously treated and well controlled
active, uncontrolled bacterial, viral or fungal infections
known infection with HIV, hepatitis B or hepatitis C
pregnant or breast-feeding patients

Contact the study team to confirm eligibility.

Othercollaborator

American Association for Cancer Research

Othercollaborator

Molecular Diagnostic Techniques

Nucleic Acid Hybridization

Primary Completion

November 2011

Actual (reported)

Study Completion

February 2012

Actual (reported)

Last Updated

July 17, 2012

Record last verified: 2012-07

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01196247
Data provider: ClinicalTrials.gov
Source updated: 2012-07-17
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:20:03 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations